Sign up to receive a link to the event and a reminder

Some 5.7 million Americans are living with Alzheimer's, and that number is expected to increase to 7.1 million in 2025 and 13.8 million by 2050.

We need a cure. NOW.

In recent years, most major pharmaceuticals have cut back on Alzheimer’s R&D as unprofitable, while smaller scientist-led companies are left struggling for investment, stifling progress.

The good news is that research scientists are discovering many promising pathways to a cure. The bad news is that large pharmaceutical companies are cutting back on Alzheimer's research and development because they view it as unprofitable, and smaller scientist-led companies simply don't have the necessary funding to pursue the research through clinical trials. This bottleneck stops promising research from being pursued.

Max Tokarsky has founded InvestAcure, a Public Benefit Corporation that will allow millions of people to invest their spare change in companies working on a cure for Alzheimer's. The vision is to see a world where drug companies are owned by spare-change investors motivated primarily by the search for a cure. As shareholders, we could hold companies accountable to put cure over profit and ensure needed investment for drug discovery and clinical trials. The result will be more clinical trials, more drugs and drug combinations tested, and more progress toward a cure.

For additional information about InvestAcure, PBC, visit or email For information about Julie A. Fleming and the Purple Sherpa, visit